OPKO Health, Inc. (OPK)
USD 1.46
(-4.58%)
USD 1.46
(-4.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -188.86 Million USD | 42.42% |
| 2022 | -328 Million USD | -1011.86% |
| 2021 | -29.5 Million USD | -196.45% |
| 2020 | 30.58 Million USD | 109.8% |
| 2019 | -312 Million USD | -103.92% |
| 2018 | -153 Million USD | 49.88% |
| 2017 | -305.25 Million USD | -1116.14% |
| 2016 | -25.1 Million USD | 16.33% |
| 2015 | -30 Million USD | 82.53% |
| 2014 | -171.7 Million USD | -50.08% |
| 2013 | -114.4 Million USD | -293.85% |
| 2012 | -29.04 Million USD | -2164.07% |
| 2011 | -1.28 Million USD | 93.22% |
| 2010 | -18.92 Million USD | 37.15% |
| 2009 | -30.11 Million USD | 24.4% |
| 2008 | -39.83 Million USD | 85.16% |
| 2007 | -268.4 Million USD | -41320.52% |
| 2006 | -648 Thousand USD | -248.39% |
| 2005 | -186 Thousand USD | 90.34% |
| 2004 | -1.92 Million USD | 66.75% |
| 2003 | -5.79 Million USD | 44.07% |
| 2002 | -10.35 Million USD | -17.91% |
| 2001 | -8.78 Million USD | -22.61% |
| 2000 | -7.16 Million USD | -64.45% |
| 1999 | -4.35 Million USD | -61.37% |
| 1998 | -2.7 Million USD | 18.18% |
| 1997 | -3.3 Million USD | -13.79% |
| 1996 | -2.9 Million USD | -7.41% |
| 1995 | -2.7 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -81.83 Million USD | -23.05% |
| 2024 Q2 | -10.3 Million USD | 87.41% |
| 2023 Q2 | -19.64 Million USD | -7.91% |
| 2023 FY | -188.86 Million USD | 42.42% |
| 2023 Q4 | -66.5 Million USD | 21.29% |
| 2023 Q3 | -84.5 Million USD | -330.24% |
| 2023 Q1 | -18.2 Million USD | 78.64% |
| 2022 Q1 | -55.38 Million USD | 24.95% |
| 2022 FY | -328 Million USD | -1011.86% |
| 2022 Q3 | -86.04 Million USD | 15.35% |
| 2022 Q4 | -85.2 Million USD | 0.99% |
| 2022 Q2 | -101.65 Million USD | -83.54% |
| 2021 Q1 | 31.07 Million USD | -3.78% |
| 2021 Q2 | -16.18 Million USD | -152.08% |
| 2021 Q3 | 28.73 Million USD | 277.55% |
| 2021 Q4 | -73.8 Million USD | -356.79% |
| 2021 FY | -29.5 Million USD | -196.45% |
| 2020 FY | 30.58 Million USD | 109.8% |
| 2020 Q4 | 32.3 Million USD | 36.19% |
| 2020 Q2 | 33.7 Million USD | 157.0% |
| 2020 Q3 | 23.71 Million USD | -29.63% |
| 2020 Q1 | -59.13 Million USD | 47.39% |
| 2019 Q3 | -62 Million USD | -3.68% |
| 2019 Q1 | -80.8 Million USD | -6.18% |
| 2019 Q2 | -59.8 Million USD | 25.98% |
| 2019 Q4 | -112.4 Million USD | -81.27% |
| 2019 FY | -312 Million USD | -103.92% |
| 2018 Q1 | -43.1 Million USD | 79.85% |
| 2018 Q3 | -27.65 Million USD | -345.98% |
| 2018 FY | -153 Million USD | 49.88% |
| 2018 Q4 | -76.1 Million USD | -175.18% |
| 2018 Q2 | -6.2 Million USD | 85.61% |
| 2017 Q3 | -46.44 Million USD | -164.96% |
| 2017 FY | -305.25 Million USD | -1116.14% |
| 2017 Q4 | -213.9 Million USD | -360.57% |
| 2017 Q2 | -17.52 Million USD | 43.45% |
| 2017 Q1 | -30.99 Million USD | -126.24% |
| 2016 Q4 | -13.7 Million USD | 8.67% |
| 2016 Q3 | -15 Million USD | -196.57% |
| 2016 Q1 | -11.97 Million USD | -848.63% |
| 2016 Q2 | 15.53 Million USD | 229.68% |
| 2016 FY | -25.1 Million USD | 16.33% |
| 2015 Q2 | -42.76 Million USD | 63.48% |
| 2015 Q4 | 1.6 Million USD | -98.75% |
| 2015 FY | -30 Million USD | 82.53% |
| 2015 Q1 | -117.11 Million USD | -120.97% |
| 2015 Q3 | 128.24 Million USD | 399.88% |
| 2014 Q2 | -25.48 Million USD | 42.81% |
| 2014 FY | -171.7 Million USD | -50.08% |
| 2014 Q4 | -53 Million USD | -8.9% |
| 2014 Q1 | -44.55 Million USD | -165.18% |
| 2014 Q3 | -48.66 Million USD | -91.01% |
| 2013 Q2 | -3.39 Million USD | 90.08% |
| 2013 Q3 | -59.99 Million USD | -1667.77% |
| 2013 Q1 | -34.21 Million USD | -6143.61% |
| 2013 FY | -114.4 Million USD | -293.85% |
| 2013 Q4 | -16.8 Million USD | 72.0% |
| 2012 Q1 | -8.61 Million USD | -146.79% |
| 2012 Q2 | -10.24 Million USD | -18.98% |
| 2012 Q3 | -9.64 Million USD | 5.85% |
| 2012 FY | -29.04 Million USD | -2164.07% |
| 2012 Q4 | -548 Thousand USD | 94.32% |
| 2011 Q3 | -8.23 Million USD | -43.33% |
| 2011 FY | -1.28 Million USD | 93.22% |
| 2011 Q4 | 18.4 Million USD | 323.45% |
| 2011 Q1 | -5.7 Million USD | -747.55% |
| 2011 Q2 | -5.74 Million USD | -0.74% |
| 2010 Q2 | -6.21 Million USD | -32.69% |
| 2010 Q1 | -4.68 Million USD | 48.45% |
| 2010 FY | -18.92 Million USD | 37.15% |
| 2010 Q4 | -673 Thousand USD | 90.85% |
| 2010 Q3 | -7.35 Million USD | -18.33% |
| 2009 Q3 | -6.35 Million USD | -11.95% |
| 2009 Q4 | -9.08 Million USD | -43.0% |
| 2009 Q1 | -8.99 Million USD | 7.7% |
| 2009 FY | -30.11 Million USD | 24.4% |
| 2009 Q2 | -5.67 Million USD | 36.91% |
| 2008 Q4 | -9.74 Million USD | -17.06% |
| 2008 FY | -39.83 Million USD | 85.16% |
| 2008 Q1 | -10.88 Million USD | -21.19% |
| 2008 Q2 | -10.87 Million USD | 0.01% |
| 2008 Q3 | -8.32 Million USD | 23.46% |
| 2007 Q1 | -249.93 Million USD | -67817.12% |
| 2007 Q4 | -8.97 Million USD | -706.21% |
| 2007 Q3 | 1.48 Million USD | 113.5% |
| 2007 Q2 | -10.97 Million USD | 95.61% |
| 2007 FY | -268.4 Million USD | -41320.52% |
| 2006 Q4 | -368 Thousand USD | -119.05% |
| 2006 FY | -648 Thousand USD | -248.39% |
| 2006 Q1 | -43 Thousand USD | 87.05% |
| 2006 Q2 | -68 Thousand USD | -58.14% |
| 2006 Q3 | -168 Thousand USD | -147.06% |
| 2005 Q3 | 871 Thousand USD | 300.69% |
| 2005 FY | -186 Thousand USD | 90.34% |
| 2005 Q4 | -332 Thousand USD | -138.12% |
| 2005 Q1 | -290 Thousand USD | -0.69% |
| 2005 Q2 | -434 Thousand USD | -49.66% |
| 2004 FY | -1.92 Million USD | 66.75% |
| 2004 Q4 | -288 Thousand USD | 21.74% |
| 2004 Q3 | -368 Thousand USD | 30.7% |
| 2004 Q2 | -531 Thousand USD | 28.15% |
| 2004 Q1 | -739 Thousand USD | 50.27% |
| 2003 Q2 | -1.79 Million USD | -81.86% |
| 2003 Q3 | -1.52 Million USD | 15.04% |
| 2003 Q4 | -1.48 Million USD | 2.56% |
| 2003 Q1 | -987 Thousand USD | 75.46% |
| 2003 FY | -5.79 Million USD | 44.07% |
| 2002 Q4 | -4.02 Million USD | -49.96% |
| 2002 Q2 | -1.88 Million USD | -6.56% |
| 2002 Q1 | -1.76 Million USD | -1.38% |
| 2002 Q3 | -2.68 Million USD | -42.28% |
| 2002 FY | -10.35 Million USD | -17.91% |
| 2001 Q3 | -2.75 Million USD | 6.68% |
| 2001 FY | -8.78 Million USD | -22.61% |
| 2001 Q1 | -1.34 Million USD | 10.25% |
| 2001 Q2 | -2.94 Million USD | -120.07% |
| 2001 Q4 | -1.74 Million USD | 36.59% |
| 2000 Q1 | -2.41 Million USD | -66.03% |
| 2000 Q4 | -1.49 Million USD | 23.75% |
| 2000 Q3 | -1.95 Million USD | -51.2% |
| 2000 Q2 | -1.29 Million USD | 46.47% |
| 2000 FY | -7.16 Million USD | -64.45% |
| 1999 Q2 | -800 Thousand USD | 27.27% |
| 1999 Q1 | -1.1 Million USD | -37.5% |
| 1999 FY | -4.35 Million USD | -61.37% |
| 1999 Q3 | -1 Million USD | -25.0% |
| 1999 Q4 | -1.45 Million USD | -45.7% |
| 1998 FY | -2.7 Million USD | 18.18% |
| 1998 Q3 | -1 Million USD | -400.0% |
| 1998 Q2 | -200 Thousand USD | 75.0% |
| 1998 Q1 | -800 Thousand USD | 0.0% |
| 1998 Q4 | -800 Thousand USD | 20.0% |
| 1997 Q1 | -700 Thousand USD | 12.5% |
| 1997 Q2 | -800 Thousand USD | -14.29% |
| 1997 Q3 | -900 Thousand USD | -12.5% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1997 FY | -3.3 Million USD | -13.79% |
| 1996 Q2 | -700 Thousand USD | 0.0% |
| 1996 Q1 | -700 Thousand USD | 0.0% |
| 1996 FY | -2.9 Million USD | -7.41% |
| 1996 Q3 | -800 Thousand USD | -14.29% |
| 1996 Q4 | -800 Thousand USD | 0.0% |
| 1995 FY | -2.7 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -113.45% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -1798.682% |
| Aspira Women's Health Inc. | -16.69 Million USD | -1031.594% |
| Biodesix, Inc. | -52.14 Million USD | -262.181% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -7083.717% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2279.523% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2279.523% |
| Bionano Genomics, Inc. | -232.49 Million USD | 18.766% |
| CareDx, Inc | -190.28 Million USD | 0.747% |
| Check-Cap Ltd. | -17.56 Million USD | -975.04% |
| Castle Biosciences, Inc. | -57.46 Million USD | -228.652% |
| DarioHealth Corp. | -59.42 Million USD | -217.807% |
| Exact Sciences Corporation | -204.14 Million USD | 7.488% |
| Fulgent Genetics, Inc. | -167.82 Million USD | -12.536% |
| Guardant Health, Inc. | -479.44 Million USD | 60.608% |
| ICON Public Limited Company | 612.33 Million USD | 130.843% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 122.35% |
| Illumina, Inc. | -1.16 Billion USD | 83.733% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -1759.481% |
| iSpecimen Inc. | -11.09 Million USD | -1601.547% |
| Standard BioTools Inc. | -74.65 Million USD | -152.978% |
| MDxHealth SA | -43.1 Million USD | -338.197% |
| 23andMe Holding Co. | -666.7 Million USD | 71.672% |
| Medpace Holdings, Inc. | 282.81 Million USD | 166.781% |
| Myriad Genetics, Inc. | -112 Million USD | -68.628% |
| Mainz Biomed B.V. | -26.29 Million USD | -618.227% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -1777.319% |
| NeoGenomics, Inc. | -87.96 Million USD | -114.695% |
| Neogen Corporation | -9.42 Million USD | -1904.702% |
| Inotiv, Inc. | -105.14 Million USD | -79.63% |
| Natera, Inc. | -434.8 Million USD | 56.563% |
| OpGen, Inc. | -32.66 Million USD | -478.119% |
| Psychemedics Corporation | -4.15 Million USD | -4446.533% |
| Prenetics Global Limited | -62.72 Million USD | -201.102% |
| Prenetics Global Limited | -62.72 Million USD | -201.102% |
| Precipio, Inc. | -5.85 Million USD | -3126.773% |
| Personalis, Inc. | -108.29 Million USD | -74.395% |
| RadNet, Inc. | 3.04 Million USD | 6304.435% |
| Sera Prognostics, Inc. | -36.24 Million USD | -421.116% |
| Sotera Health Company | 51.37 Million USD | 467.609% |
| Neuronetics, Inc. | -30.18 Million USD | -525.602% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -12100.452% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -12100.452% |
| Trinity Biotech plc | -24.01 Million USD | -686.339% |
| T2 Biosystems, Inc. | -50.07 Million USD | -277.145% |
| Twist Bioscience Corporation | -208.72 Million USD | 9.516% |
| Exagen Inc. | -23.68 Million USD | -697.26% |